Oppenheimer Holdings, Inc. set a $135.00 price target on Incyte Corporation (NASDAQ:INCY) in a report published on Tuesday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on INCY. Cowen and Company reiterated an outperform rating and issued a $130.00 price objective on shares of Incyte Corporation in a research report on Monday, July 3rd. Barclays PLC lifted their price objective on Incyte Corporation from $135.00 to $185.00 and gave the company an overweight rating in a research report on Tuesday, July 4th. Jefferies Group LLC reiterated a buy rating and issued a $165.00 price objective on shares of Incyte Corporation in a research report on Tuesday, July 4th. BidaskClub downgraded Incyte Corporation from a buy rating to a hold rating in a research report on Thursday, July 6th. Finally, Credit Suisse Group set a $152.00 price objective on Incyte Corporation and gave the company a buy rating in a research report on Sunday, July 16th. Seven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Incyte Corporation has an average rating of Buy and an average target price of $144.98.

Shares of Incyte Corporation (NASDAQ INCY) traded down 2.230% on Tuesday, hitting $110.725. The stock had a trading volume of 809,043 shares. Incyte Corporation has a 52 week low of $83.01 and a 52 week high of $153.15. The firm has a 50 day moving average price of $114.88 and a 200-day moving average price of $124.14. The company’s market cap is $22.78 billion.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. During the same quarter in the previous year, the company posted $0.19 EPS. The business’s revenue for the quarter was up 41.6% compared to the same quarter last year. Analysts anticipate that Incyte Corporation will post ($0.82) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (INCY) Given a $135.00 Price Target by Oppenheimer Holdings, Inc. Analysts” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2017/11/01/incyte-corporation-incy-given-a-135-00-price-target-by-oppenheimer-holdings-inc-analysts.html.

In related news, insider Paul Trower sold 3,000 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $125.25, for a total transaction of $375,750.00. Following the sale, the insider now owns 11,853 shares of the company’s stock, valued at $1,484,588.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker purchased 100,000 shares of Incyte Corporation stock in a transaction that occurred on Friday, September 8th. The shares were bought at an average cost of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Insiders sold 101,147 shares of company stock worth $12,615,101 in the last 90 days. Corporate insiders own 17.70% of the company’s stock.

A number of large investors have recently modified their holdings of INCY. Wetherby Asset Management Inc. boosted its holdings in shares of Incyte Corporation by 1.4% in the 2nd quarter. Wetherby Asset Management Inc. now owns 1,672 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 23 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of Incyte Corporation by 0.8% during the 2nd quarter. Nordea Investment Management AB now owns 8,179 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 67 shares in the last quarter. Grandfield & Dodd LLC boosted its holdings in shares of Incyte Corporation by 1.2% during the 2nd quarter. Grandfield & Dodd LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $930,000 after acquiring an additional 85 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Incyte Corporation by 9.9% during the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 103 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Incyte Corporation by 13.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 108 shares in the last quarter. 88.85% of the stock is currently owned by institutional investors and hedge funds.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.